Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response
Norihiro Awaya, MD, PhD
Principal Investigator
Keio University School of Medicine
Japan: Ministry of Health, Labor and Welfare
17-40
NCT00367497
August 2005
November 2007
Name | Location |
---|